Downside risks are clear and present but 5-, 10-year outlooks solid, strategists say.
With a gain of more than 28% from the start of the year, small-caps have outperformed large-caps by 8 percentage points.
Stock prices surged the most since January as signs emerged that lawmakers were inching toward a deal to increase the debt ceiling and avert a default. But it could all turn on a dime.
S&P 500 Index reaches highest level since September.
No panic as many see last-minute deal getting done.
The combination of a weak outlook for bonds and research that investors close to retirement are OK with more risk leads Fidelity to tilt its target date funds more toward stocks.
Strategist Bob Doll lends investment expertise to offering expected in early 2014.
Stocks could lose 40% to 50% of value over next few years, analyst says
Deal adds six equities strategies, pushes firm over $500M in assets.
ETFs can help investors remain 'agile and active,' COO says.
Even though the partial shutdown of the government is set to give way to a prolonged — and probably nasty — debt-ceiling debate, now is not the time to bail from the markets.
Returns from the stock market's four-year rally match those of the late-1990s advance, but valuations are lagging. Bulls say that means there's more room to run; bears have a compelling counter argument.
Analyst says rally based on rising interest rates, a likelihood pushed into future.
The Fed's unexpected change of heart has some advisers looking for a near-term rally in bonds. Jeff Benjamin has the story.
King Pharmaceuticals-Pfizer deal led to nearly $500,000 in illegal profits, agency claims.
Study by Harold Evensky finds that belief is more sales pitch than reality.
Live from the <i>IN</i> Alternatives Investments Conference: Low rates, economic uncertainty and surprises have pushed asset classes in the same direction
